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Comprehensive analysis of cancer-associated somatic mutations in class I
HLA genes
Abstract
Detection of somatic mutations in human leukocyte antigen (HLA) genes using whole-exome sequencing
(WES) is hampered by the high polymorphism of the HLA loci, which prevents alignment of sequencing
reads to the human reference genome. We describe a computational pipeline that enables accurate inference
of germline alleles of class I HLA-A, B and C genes and subsequent detection of mutations in these genes
using the inferred alleles as a reference. Analysis of WES data from 7,930 pairs of tumor and healthy tissue
from the same patient revealed 298 nonsilent HLA mutations in tumors from 266 patients. These 298
mutations are enriched for likely functional mutations, including putative loss-of-function events. Recurrence
of mutations suggested that these 'hotspot' sites were positively selected. Cancers with recurrent somatic HLA
mutations were associated with upregulation of signatures of cytolytic activity characteristic of tumor
infiltration by effector lymphocytes, supporting immune evasion by altered HLA function as a contributory
mechanism in cancer.
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Abstract
Detection of somatic mutations in HLA genes using whole-exome sequencing (WES) is hampered 
by the high polymorphism of the HLA loci, which prevents alignment of sequencing reads to the 
human reference genome. We describe a computational pipeline that enables accurate inference of 
germline alleles of class I HLA-A, -B and -C genes and subsequent detection of mutations in these 
genes using the inferred alleles as a reference. Analysis of WES data from 7,930 pairs of tumor 
and healthy tissue from the same patient revealed 298 non-silent HLA mutations in tumors from 
266 patients. These 298 mutations are enriched for likely functional mutations, including putative 
loss-of-function events. Recurrence of mutations suggested that these ‘hotspot’ sites were 
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positively selected. Cancers with recurrent somatic HLA mutations were associated with 
upregulation of signatures of cytolytic activity characteristic of tumor infiltration by effector 
lymphocytes, supporting immune evasion by altered HLA function as a contributory mechanism 
in cancer.
Recent large-scale WES studies have revealed the existence and relative high frequency of 
somatic changes in HLA class I genes in head and neck cancer, squamous cell lung cancer, 
stomach adenocarcinoma and diffuse large B cell lymphoma1–5. The HLA locus, located on 
chromosome 6, is among the most polymorphic regions of the human genome, with 
thousands of documented alleles for each gene6. These class I alleles are critical mediators 
of the cytotoxic T cell response, presenting cellular peptides on the cell surface in a form 
that can be recognized by the T cell receptor7, 8. The finding of enhanced somatic mutation 
rate in HLA genes has strongly implicated HLA dysfunction as a possible mechanism of 
immune evasion in the development and progression of certain cancers1–5.
Each individual expresses six major MHC class I alleles, encoded by three genes (HLA-A, 
HLA-B and HLA-C) located on the two homologous copies of chromosome 6. Conventional 
determination of HLA type is performed using serology- and/or PCR-based methods that are 
labor-intensive and time-consuming9–11. Several protocols have recently been proposed for 
HLA-targeted multiplexed PCR coupled with next generation sequencing (NGS), but by 
design, provide information restricted to HLA alleles, and not the rest of genome12–16. 
Theoretically HLA typing information should be directly extractable from WES data, an 
increasingly available and cost-effective approach for the comprehensive analysis of 
genome-wide somatic alterations. The human reference genome, however, has a single 
sequence for each HLA gene and would likely misrepresent the true alleles in the individual, 
thereby causing suboptimal alignments. In addition, the HLA genes are GC-rich and 
therefore typically suffer from lower sequencing coverage due to lower efficiency in capture 
and amplification and increased sequencing errors that further reduce the alignment rates. 
Consequently, in order to accurately detect somatic mutations in the HLA genes, one needs 
first to accurately align all reads originating from this region in both the tumor and matched 
normal samples and only then apply somatic mutation detection tools. We also surmised that 
conventional alignment and mutation detection methods, which do not carefully treat this 
highly polymorphic region, would be prone to errors.
To this end, we developed the algorithm POLYSOLVER (POLYmorphic loci reSOLVER), 
which enables high precision HLA-typing even while using relatively low coverage WES 
data, and a subsequent mutation detection pipeline that uses the inferred alleles as a basis for 
high fidelity detection of mutations in HLA genes. By analyzing WES data from 7,930 
cancer patients we demonstrate high sensitivity and specificity of our method in detecting 
HLA somatic mutations. Further characterization suggests a functional impact of these 
mutations on this biologically important and complex locus. POLYSOLVER is freely 
available for noncommercial use at http://www.broadinstitute.org/cancer/cga/polysolver 
(Supplementary Data).
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RESULTS
Inference of class I HLA alleles using POLYSOLVER
In order to develop POLYSOLVER, we collected a training set of 8 chronic lymphocytic 
leukemia (CLL) patients for which WES data as well as conventional PCR-based HLA 
typing were available17 (Supplementary Table 1). We first confirmed the expected poor 
coverage and inverse correlation between GC content and coverage in HLA genes in this set 
(Supplementary Fig. 1). We reasoned that coverage at these highly polymorphic regions can 
be substantially improved by ensuring retrieval of true HLA reads that failed to align to the 
canonical reference, followed by alignment to a library of all known HLA alleles. These 
alignments could then be used for subsequent computational inference of the individual’s 
HLA type. Thus, POLYSOLVER consists of the following steps: (i) improved retrieval and 
alignment of HLA reads; (ii) inference of the HLA alleles using a two-step Bayesian 
classification approach (Fig. 1a and Supplementary Methods). In brief, we increased the 
precision of the alignment by first selecting reads from the WES data that potentially 
originated from the HLA region (Supplementary Fig. 2) and aligning them to a full-length 
genomic library of all known HLA alleles based on the IMGT database18 (Online Methods) 
using a precise alignment method (Novoalign, www.novocraft.com), keeping all best-
scoring alignments for each read for use in subsequent steps. Inference of the two alleles for 
each HLA gene was based on a Bayesian calculation that takes into account the base 
qualities of aligned reads, observed insert sizes, as well as the ethnicity-dependent prior 
probabilities of each allele12, 19 (Supplementary Table 2).
For validation, we applied POLYSOLVER to WES data from an independent set of 253 
HapMap samples with known HLA genotypes (Supplementary Tables 3 and 4). We 
observed that POLYSOLVER achieved an overall mean sensitivity of 97% (83% samples 
had all allele species correctly identified), overall mean precision of 98.8% (93.6% samples 
had no incorrectly identified allele species), mean overall accuracy of 97% (83% samples 
had all alleles correctly called), and 100% homozygosity success rate (83 of 83 homozygous 
cases correctly identified) in HLA typing at the protein coding level. Compared to other 
recently reported algorithms for inference of HLA type directly from whole-exome 
sequencing data, POLYSOLVER outperformed 4 of 5 other tools, and was of comparable 
performance to the recently described OptiType tool20 (Fig. 1b, Supplementary Table 4 and 
Supplementary Methods). To accommodate future use of POLYSOLVER for samples of 
unknown ethnic origin, we developed a principal components (PC)-based method for 
exome-based ethnicity inference (Online methods and Supplementary Fig. 3), which can be 
used prior to analysis by POLYSOLVER to ensure maximal typing accuracy.
Detection of somatic mutations within the HLA region
A standard approach for detection of somatic mutations is to first align both tumor and 
normal reads to the reference genome and then scan the genome and identify mutational 
events observed in the tumor but not in the matched normal (e.g. as implemented in 
MuTect21). We reasoned that the accurate detection of individual native HLA type using 
germline data by POLYSOLVER could substantially improve alignment of reads (in both 
tumor and normal) and hence improve the sensitivity and specificity of somatic mutation 
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calling within the HLA region (Fig. 2a). In this setting, the inferred allele species for each 
HLA gene would serve as patient-specific reference ‘chromosomes’ against which pre-
selected HLA reads from the tumor and germline samples are aligned separately followed by 
standard mutation calling. We therefore built an analysis pipeline to call somatic mutations 
in the HLA genes that includes the following steps: (i) ethnicity detection using the normal 
sample; (ii) inference of HLA type by applying POLYSOLVER on the normal sample 
(although other highly accurate HLA typing tools could also be used); (iii) re-alignment of 
the HLA reads in both tumor and normal to the inferred HLA alleles while filtering out 
likely erroneous alignments (Online methods); (iv) application of standard tools to detect 
somatic mutations (MuTect21 and Strelka22) by comparing the re-aligned tumor and normal 
HLA reads.
To test this approach, we initially assembled a dataset of 2,545 cases of matched tumor and 
germline DNA spanning 12 tumor types – 10 from The Cancer Genome Atlas project 
(TCGA), and two separate genomic studies focusing on chronic lymphocytic leukemia and 
melanoma. 59 HLA gene somatic mutations were previously detected using standard 
methods (Supplementary Methods) and reported as part of a pan-cancer analysis effort23 
(Online Methods)17, 24. On re-analysis of these cases with our POLYSOLVER-based 
mutation detection pipeline, we detected 36 of 59 (61%) previously reported HLA 
mutations, as well as 37 novel somatic HLA mutations; in total, 73 mutations in 64 of 2,545 
cases (Fig. 2b, Fig. 2c and Supplementary Tables 5–7). Manual review of all HLA mutation 
events using IGV25 suggested that 9 of 23 mutations identified exclusively by TCGA were 
true events, of which 6 were just below the detection limit of our pipeline and were 
identified once we slightly relaxed the read filtering criteria used prior to mutation calling 
(Supplementary Table 8 and Supplementary Methods).
When available, we examined matched RNA-Sequencing data and sought orthogonal 
evidence of expression of the somatically mutated HLA allele that was detected by WES 
(indel calls were excluded from this analysis due to low reliability of indel alignment and 
detection by RNA-Seq26). A mutation was considered validated if there were at least two 
alternate allele bearing reads in the RNA-Seq data for well-powered sites (Online methods). 
In total, we could evaluate RNA-Seq data for 49 of 96 mutations, including 10 that were 
exclusively reported by TCGA, 17 detected only by our pipeline and 22 that were detected 
by both. We observed a high rate of RNA-Seq based validation of missense, nonsense and 
splice-site mutations in the set of 22 mutations found in common (8 of 8; 8 of 11; and 2 of 3 
events, respectively; Fig. 2d and Supplementary Table 9). We likewise observed high rates 
of validation for events identified exclusively by the POLYSOLVER-based mutation 
detection pipeline (7 of 9; 5 of 6; and 2 of 2 events respectively). By contrast, only 2 of 10 
mutations uniquely identified by TCGA were validated using RNA-Seq.
We further performed experimental validation of inferred mutation calls through direct 
targeted sequencing of HLA-A and HLA-B alleles of 18 TCGA samples identified as bearing 
HLA mutations for which DNA material was available (Online Methods)27. 6 of these 18 
samples did not have adequate coverage at the site of mutation and were removed from the 
analysis due to power considerations (Online Methods). Of the remaining 12 mutations, this 
analysis confirmed all 11 of 11 HLA mutations that were inferred by the POLYSOLVER-
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based mutation detection pipeline (5 identified by TCGA also; 6 identified exclusively by 
POLYSOLVER), while the sole mutation identified exclusively by TCGA did not validate 
(Fig. 2d and Supplementary Table 10). Altogether, these results demonstrate that the 
POLYSOLVER-based approach is both a sensitive and specific somatic mutation detection 
strategy within the highly polymorphic HLA loci.
Patterns of somatic HLA mutation across tumor types
We extended our analysis of POLYSOLVER-based mutation detection to a total of 7,930 
TCGA tumor/normal pairs (including the original collection of 2,545 and 5,385 additional 
cases). In total, we detected 298 somatic HLA mutations in 266 of 7,930 (3.3%) individuals 
(Supplementary Tables 11 and 12). The median allele fraction across somatic changes was 
33% (interquartile range: 16 – 58%) suggesting that most of these mutations are 
heterozygous (Supplementary Fig. 4a).
Amongst the cancer types, we observed differences in frequency, localization and types of 
somatic HLA mutations (Fig. 3). In addition to finding HLA mutations occurring 
significantly in head and neck (HLA-A, HLA-B), lung squamous (HLA-A) and stomach 
(HLA-B) cancer as previously reported, we now further identified HLA-A (FDR q=2.3×10−8) 
and HLA-B (FDR q=3.9×10−7) to be significantly mutated in colon adenocarcinoma. By 
contrast, chronic lymphocytic leukemia (n=128) and liver cancer (n=202) entirely lacked 
HLA mutations, and only single mutations were detected in glioblastoma (n=390) and 
ovarian cancer (n=432). 214 of 298 HLA mutations (71.8%) fell in 64 recurrent positions 
(i.e. amino acids that were mutated in at least two instances). The recurrent sites were 
distributed across the HLA gene (median of 2 mutated cases/recurrent site (range 2–24), Fig. 
3-bottom, Supplementary Table 13 and Supplementary Fig. 4b–c).
Somatic class I HLA mutations are enriched for localization at sites affecting peptide-MHC 
interaction and are likely positively selected
Alterations highly likely to have a functional effect, including loss-of-function events 
(nonsense, frameshift indels, splice site), were significantly enriched in HLA mutations 
compared to non-HLA mutations (Fig. 4a, chi-squared test P < 2.2 × 10−16). We also 
observed that while potentially loss-of-function mutations occur in all functional domains of 
the HLA molecule, they demonstrated a strong preference for the N-terminal end in the 
leader peptide sequence (P=0.0038), which would likely result in a completely non-
functional protein (Supplementary Fig. 4d). The highest frequency of mutations occurred in 
exon 4 (118 mutations, 39.6%) which encodes the α3 domain of the HLA protein that binds 
to the CD8 co-receptor of T cells28 (Fig. 4b). Abrogation of this function could lead to a loss 
of T cell recognition and thereby a loss of immune reactivity. The second highest frequency 
of mutations occurred in exon 3 (56 mutations, 18.8%) followed by exon 2 (49 mutations, 
16.4%), which encode the α1 and α2 peptide binding domains of the HLA molecule 
respectively which conventionally bind 9- and 10-mer peptides for antigen presentation29.
Analysis of the position of the mutated residues within exons 2 and 3 in relationship to their 
predicted interaction with binding peptide29 further strongly suggests alteration of immune 
function by these somatic HLA mutations (Supplementary Table 14). The two major anchor 
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grooves in the HLA molecule bind to positions 2 and 9 respectively of the peptide, and 
mutation in either groove would be expected to profoundly affect the biochemical stability 
of the MHC-peptide complex29. A secondary anchor groove that interacts primarily with the 
sixth amino acid of the peptide lies between the two primary anchor grooves30. Overall, 
28.6% of mutations (30 of 105) in the peptide binding domains were in residues that come in 
contact with the peptide and 80% (24 of 30) of these were in positions that comprised one of 
the two primary anchor grooves (Fig. 4c).
We hypothesized that loss-of-function HLA mutations would more likely arise in the 
presence of selective pressure imposed by the host immune response against the tumor. A 
growing body of studies has shown that higher mutational burdens in cancers give rise to a 
higher load of mutation-derived immunogenic epitopes and that immune responses against 
these are associated with clinical benefit31. These immune responses are presumably driven 
by the presentation of tumor-derived epitopes by antigen presenting cells to stimulate 
effector lymphocyte responses. Consistent with the idea that a tumor would evolve in a 
manner to escape recognition and destruction by tumor-directed T or NK cells, we detected 
an association between the presence of HLA somatic mutations and tumor expression 
signatures consistent with infiltration by effector lymphocytes, as recently defined32 
(Supplementary Table 15 and Fig. 4d). Although putative loss-of-function somatic 
mutations in tumor HLA genes could lead to a decrease in the presentation of immunogenic 
epitopes by the tumor cell and evasion of immunologic targeting, these same mutations 
would not impact the ability of non-tumor host antigen-presenting cells to ingest and present 
tumor antigens to T cells, thereby stimulating immune infiltration. For these analyses, we 
examined the expression of 18,000 genes in matched RNA-Seq data from 4,512 samples 
across 11 tumor types and found the strongest associations in 6 of 11 cancer types (stomach, 
endometrial, cervical, head and neck, colorectal, and glioma), suggesting that reduced MHC 
class I activity may be particularly important for driving immune escape in these tumor 
types. From this unbiased analysis, the most significantly enriched genes were interferon 
gamma (IFNG), T cell attractive chemokines (CXCL9, CXCL10, CXCL11), lytic molecules 
(GZMA, GZMH, PRF1, GNLY), as well as the “Cytolytic Activity” metagene (analyzed 
previously as a measure of anti-tumor T/NK cell activity32). These results suggest that 
acquisition of HLA mutations without abrogation of expression may provide a 
complementary immunosurveillance escape mechanism in which potential destruction of the 
tumor by T cells and natural killer (NK) cells is precluded.
DISCUSSION
Immune evasion is a critical process in tumor biology and is enabled by several mechanisms 
including immune-editing33, down-regulation of HLA expression34, secretion of 
immunosuppressive mediators35, and expression of proteins that modulate immune 
checkpoints36. Most recently, somatic mutation of HLA genes was revealed to be a 
significantly frequent process in some tumor types4. Improved sensitivity and accuracy of 
somatic HLA mutation detection could better characterize this already strongly implicated 
mechanism of immune evasion across cancers. We therefore created POLYSOLVER, a 
model-based algorithm for accurate inference of HLA typing information from germline 
exome-capture data which enables more sensitive and specific detection of somatic HLA 
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mutations compared to standard techniques reliant on alignment to the canonical reference 
genome.
We have demonstrated that POLYSOLVER infers HLA-type information with 97% 
sensitivity and 98% precision from exome-capture sequencing data and is among the best-
performing tools for the analysis of HLA loci from WES data. Indeed, different typing tools, 
or a combination thereof, may be used for optimizing different aspects of HLA mutation 
detection performance, e.g. a consensus approach that only uses allele species commonly 
identified by multiple tools as basis for mutation detection would favor increased specificity 
at the cost of sensitivity. The improved performance of HLA mutation detection was 
assessed to be primarily due to use of inferred alleles as reference and employment of 
stringent criteria for filtering aligned reads prior to mutation calling. We estimate an 
increase in sensitivity from 58.8% to 94.1% and specificity from 20% to 53.3% over 
standard methods based on validation of point mutations in RNA-Seq data, a performance 
similar to that of the recently published OptiType tool20. An expected limitation of 
POLYSOLVER is its restriction to identification of known alleles, but future versions may 
be augmented by an assembly-driven module which would enable discovery of novel HLA 
alleles, and by representing a wider range of ethnic groups. POLYSOLVER, as well as other 
available HLA typing tools that can be used with WES, are also not yet suitable for clinical 
use where much higher accuracy (>99.9%) is required. However, the POLYSOLVER-based 
mutation detection pipeline can still be used effectively for detecting somatic changes in 
HLA genes once experimentally determined HLA typing information is available.
In this study, we performed a comprehensive characterization of HLA mutations in 7,930 
samples across 20 different tumor types. We have shown that, in comparison to previous 
studies, the HLA mutational spectrum elucidated by our analysis has significantly reduced 
false positives and detects additional somatic mutations. Several biologic insights emerged 
from our analysis. First, we identified colon adenocarcinoma to be significantly affected by 
somatic mutation in class I HLA genes in addition to head and neck, lung squamous and 
stomach cancer, thus further supporting HLA mutation as a common oncogenic mechanism. 
In contrast, other cancers such as glioblastoma, ovarian cancer and chronic lymphocytic 
leukemia largely lacked mutations in HLA genes. Second, several characteristics of the 
identified nonsynonymous mutations suggest that they functionally impact antigen 
presentation. We identified 29 sites across the HLA genes that were recurrently mutated in 
at least 3 cases, and 35 sites by 2 cases suggesting positive selection at these positions. We 
further noted a significant enrichment in loss-of-function events in the HLA genes such as 
frameshifting indels, nonsense and splice site mutations. These events would be expected to 
abrogate HLA class I surface expression on tumors37–39, thereby impacting antigen 
presentation to immune cells. We determined that the majority of the detected mutations 
map to regions critical for antigen presentation. More than a third of the mutations (39.6%) 
were in exon 4 that encodes the MHC class I allele α3 domain, which binds to the CD8 co-
receptor on T cells28. Mutations in this domain have been previously shown to abrogate 
binding to CD840. Exons 2 and 3 harbored 35.2% of the mutations – these exons encode the 
surfaces that present peptides to immune cells. We found evidence that exon 2 and 3 HLA 
mutations preferentially localized to residues critical for anchoring peptide to the MHC 
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binding grooves, and would be expected to interfere with the fundamental process of antigen 
presentation29, 30.
Finally, we observed a strong association between effector lymphocyte gene expression 
signatures and HLA mutations, which is consistent with the hypothesis that somatic changes 
in these genes are a plausible immune escape mechanism that arise in response to increased 
cytolytic activity in several tumor types. However, additional experiments are required to 
better understand this mechanism.
Improvements in massively-parallel sequencing technologies are now enabling increased 
coverage and longer read lengths, which should further help POLYSOLVER in resolving 
somatic changes in HLA regions. Further efforts will be focused on extending the 
methodology to other data modalities including RNA-Seq and whole genome sequencing. In 
addition to enabling better detection of HLA mutations, accurate HLA typing by 
POLYSOLVER can also be used to study germline associations of HLA alleles in diseases 
such as autoimmune diseases and cancer. It could be used prospectively for preliminary 
screening for matches for allogeneic organ transplantation. Finally, as described in the 
current report, POLYSOLVER can be potentially extended to extract sequence and mutation 
information from other polymorphic regions in the genome such as MHC class II, non-
classical MHC alleles, TAP1 and TAP2 genes, and MIC-A and MIC-B ligands, and hence is 
a generally applicable analysis framework to address these otherwise challenging loci.
Online Methods
Whole-exome sequencing data
All samples were obtained under Institutional Review Board approval and with documented 
informed consent. A complete list of TCGA samples is given in Supplementary Table 11. 
Mutational spectra of chronic lymphocytic leukemia (CLL)17, 45 and melanoma24 have 
previously been reported, while mutations lists for lung squamous carcinoma (LUSC), lung 
adenocarcinoma (LUAD), bladder (BLCA), head and neck (HNSC), colon (COAD) and 
rectum (READ), glioblastoma (GBM), ovarian (OV), uterine corpus endometrial carcinoma 
(UCEC), and breast (BRCA) were obtained from the Sage Bionetworks’ Synapse resource 
(http://www.synapse.org/#!SYNAPSE:syn1729383). For a subset of CLL patients (N=8), 
HLA typing was performed by molecular typing (Tissue Typing Laboratory, Brigham and 
Women’s Hospital, Boston, MA) and these cases were used as a training set for the 
POLYSOLVER algorithm (Supplementary Table 1). The validation set comprised 253 
samples from 183 distinct individuals (47 Caucasians, 50 Blacks, 41 Chinese and 45 
Japanese individuals) that had both exome data and experimentally determined HLA type 
information12 (http://www.1000genomes.org).
POLYSOLVER allele database creation
To maximally retrieve true HLA reads, we constructed a full length genomic reference 
library of known HLA alleles (6597 unique entries) based on the Multiple Sequence 
Alignment (MSA) files provided in the IMGT database (v3.10; http://www.ebi.ac.uk/ipd/
imgt/hla/), similar to the approach described in Erlich et al12. We first used the cDNA file to 
impute exons in an incompletely sequenced allele by using a reference allele that had 
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protein-level identity with the allele in question, as was evident by concordance of 4-digit 
nomenclature. If no such reference allele was available, we set as reference an allele that 
derived from the same allele group, as was evident by concordance of 2-digit nomenclature. 
In cases where there were multiple such possibilities for choosing the reference allele, we 
chose the first listed allele in the MSA. A similar approach was used to impute the missing 
components of the sequences listed in genomic (gDNA) MSA file. Finally the full length 
genomic sequence of each allele was imputed by assembling exons from the cDNA 
imputation step and introns from the gDNA imputation.
Ethnicity inference and prior probability estimation
4-digit allele frequencies for different ethnicities were calculated by taking a sample-size 
weighted average of all relevant population studies in the Allele Frequency Net Database 
(http://www.allelefrequencies.net/).
A rapid principal components analysis (PCA) based method was developed to infer ethnicity 
for samples of unknown racial origin (Kiezun et al, manuscript in preparation). Exome data 
for samples of known (self-described) ethnicity from the 1000 Genomes and HapMap 
projects (n=1,398, with 911 Caucasians, 375 Blacks, 54 Asians, and 58 South Asians) was 
genotyped at a predefined set of 5,845 loci chosen based on considerations related to known 
linkage disequilibrium between different loci, representation on population genotyping 
platforms and consistency between genome releases46. A PCA revealed distinct segregation 
of Caucasian, Black, Asian, and South Asian samples in the 2-dimensional space defined by 
the first two principal components. Any new sample of unknown ethnicity can now be 
projected in this space and its Euclidean distance from the clusters centroids can be 
computed. Ethnicity is inferred based on the cluster of minimal distance from the sample 
projection.
Allele inference
The posterior probability calculations for alleles corresponding to each HLA gene (A, B or 
C) are performed separately as described below:
Let
NA ≡ # alleles corresponding to the HLA gene
N ≡ # reads aligning to at least one allele
Nm ≡ # reads aligning to allele am
NT ≡ # reads in the sequencing run
fm ≡ population based prior probability of allele m
rk1 ≡ first read of read pair rk
rk2 ≡ second read of read pair rk
dk ≡ insert length of read pair rk
lk1 ≡ length of first read of read pair rk
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lk2 ≡ length of second read of read pair rk
qi ≡ Phred-like quality of sequenced base i
ei ≡ probability that the sequenced base i is an error
The quality scores of the alignment were used to build a model for the sequencing process. 
Let us say that a given read pair rk does in fact derive from an allele am and their sequence 
relationship allowing for miscalls in the sequencing process is accurately captured in the 
alignment. Let YAi, YCi, YGi and YTi denote random variables corresponding to observing 
bases A, C, G and T respectively at position i in read pair rk in it’s alignment to allele am. 
Then
where
 if reference base at position i in am is B
=  otherwise
Let D denote a random variable for the observed insert length of a paired read in the 
sequencing run based on alignment to the complete genome. For a given read pair rk, the 
empirical insert size distribution can be used to estimate the probability of observing the 
insert length dk as
Assuming positional independence of quality scores, and independence of generated reads 
and their insert sizes, the probability of observing rk given allele am is then
where sk corresponds to the lowest theoretical probability achievable for read pair r’k with 
perfect base qualities and segment lengths equal to those of rk. Since 93 is the maximum 
achievable base quality under Illumina 1.8+ format, sk is computed as
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The posterior probability of allele am using all reads that align to it is given by
Log transformation of the above equation yields
Note that the terms N·sk and  are constants for all alleles and can be ignored. 
The first allele is inferred as the one that maximizes the posterior probability.
To infer the second allele we had to handle the fact that different alleles are very similar to 
each other, including the winning allele. Therefore, we weight reads aligning to multiple 
alleles according to the likelihood of reads with respect to the different alleles by applying a 
heuristic strategy. For a given allele am, the likelihood lmk of a read rk that also mapped to 
the winning allele aw with likelihood lwk was weighted by a factor equal to lmk/(lmk + lwk). 
Consequently, reads mapping exclusively to am with respect to aw were assigned a weight of 
1. The read insert size and allele prior probability components were preserved from the first 
allele inference step. The second winner at each locus was identified as the allele with the 
maximal reevaluated score.
Pre- and post-processing steps for HLA mutation detection
Prior to detection of somatic changes using Mutect and Strelka by comparison of tumor and 
normal HLA reads aligned to POLYSOLVER-inferred HLA alleles, the following changes 
and filters were implemented: (i) NotPrimaryAlignment bit flag was turned off from all 
alignments since several reads mapped to multiple alleles; (ii) mapping quality was changed 
to a non-zero value (=70) for all reads; (iii) alignments where both mates did not align to the 
same reference allele were discarded; and (iv) alignments where at least one mate had more 
than one mutation, insertion or deletion event compared to the reference allele were 
discarded. Soft-clipping of the reads was not allowed during the alignment. Alleles with 
multiple detected somatic changes were removed from the analysis. In cases where both 
inferred alleles were identical in the region of detected somatic mutation, the mutation was 
assigned to the more common allele in the population. All somatic events were visualized 
using IGV (Mutect: ‘KEEP’ entries in call_stats file, Strelka: All entries in 
all.somatic.indels.vcf file) and the ones that passed manual review were further annotated 
for the gene compartment (intron, exon, splice site) and protein change. Splice sites were 
defined as the set of splice consensus sequence positions that had a bit score of at least 1 in 
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either the human major/U2 or human minor/U12 introns at the exon/intron boundaries (9 
positions at the 5′ splice donor end of the intron including the ultimate base in the upstream 
exon, and 2 positions at the 3′ splice acceptor end of the intron)47.
Validation of somatic HLA mutations by RNA-Seq evaluation
The MutationValidator tool (manuscript in preparation) was used for orthogonal 
confirmation of mutations in RNA-Seq data. A mutation was considered validated in RNA-
Seq if there were at least 2 reads supporting the mutation. In brief, to determine the power, 
we first model the distribution of allelic fraction of the mutation based on the exome data as 
a Beta(a+1, r+1) distribution, where a is the number of reads bearing the alternate allele and 
r is the number of reads bearing the reference allele at the site of mutation. Then, given the 
total number of reads aligning at the position in the RNA-Seq data (N), power was 
calculated as the probability that we would detect at least two reads bearing the alternate 
allele in the RNA-Seq data (assuming it has the same underlying allele fraction as the DNA) 
using the Beta-binomial distribution Beta-Binom(N,a+1, r+1) i.e.
A threshold of 80% power was used to consider a site to be powered to detect the mutation 
in the RNA-Seq data. Sites that had less than 80% power were removed from the analysis.
Standard HLA typing
Standard HLA typing was performed at the Brigham and Women’s Hospital Tissue Typing 
Laboratory using a combination of sequence-specific oligonucleotide probe (SSO) and 
sequence specific primer (SSP) techniques. Genomic DNA samples were initially typed 
using locus specific LabType® SSO kits (One Lambda Inc.) and analyzed using a Luminex 
200. Loci for which there were more than one common well documented (CWD) allele were 
subsequently resolved by PCR-SSP kits (One Lambda Inc. and Life Technologies) and 
analyzed using gel electrophoresis.
Validation of inferred somatic HLA mutations by targeted long sequencing of HLA-A and –
B
HLA-A and HLA-B amplification of TCGA samples—HLA locus-specific 
amplification for HLA-A and HLA-B sequences were performed separately using HGSgo-
AmpX kits from GenDX (Utrecht, Netherlands). Briefly, for each sample, 100ng of genomic 
DNA was mixed with 1ul of AmpX primer (GenDX), 1.25uL dNTP mix (Qiagen), 2.5uL 
LongRange PCR Buffer (Qiagen), 0.4uL LongRange PCR Enzyme (Qiagen) and nuclease 
free water was added to a final volume of 25uL per reaction. Samples were then placed in a 
thermal cycler and PCR was performed using the following conditions: initial denaturation 
at 95°C for 3 min, followed by 35 cycles of 95°C for 15 sec., 65°C for 30 sec. and 68°C for 
6 min, followed by a final incubation at 68°C for 10 min. All PCR reactions were then 
purified using Agencourt AMPureXP beads according to the manufacturer’s protocol 
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(Beckman Coulter). Following AMPureXP purification, the concentrations of the 
amplification products (approximately 3.1–3.4 kb) were confirmed by Quant-iT (Life 
Technologies) and the sizes were confirmed using an Agilent Bioanalyzer DNA 7500 kit.
Library construction and long sequencing—SMRTbell DNA template libraries were 
prepared from the HLA-A and HLA-B amplicons according to the manufacturer’s suggested 
protocol (5kb Template Preparation and Sequencing, Pacific Biosciences). Briefly, 
equimolar pools of HLA-A and HLA-B amplicons were prepared for each sample. Pooled 
amplicons were then end repaired and ligated to barcoded SMRTbell adapters. Following 
the addition of barcoded SMRTbell adapters, all samples were pooled and exonuclease 
treated according to the manufacturer’s suggested protocol. Pooled, barcoded libraries were 
then purified using AMPure PB beads (Pacific Biosciences) and quantified using an Agilent 
Bioanalyzer DNA 7500 kit. Pooled samples were sequenced in SMRTCells using a Pacific 
Biosciences RSII instrument using the P6 DNA/Polymerase Binding Kit in conjunction with 
the DNA Sequencing Reagent 4.0. Barcoded subreads were analyzed using the SMRT 
Analysis (version 2.3.0) Long Amplicon Analysis (LAA) protocol.
Analysis—We confirmed the accuracy of the Pacific Biosciences-based long sequencing 
approach through testing 6 samples from normal volunteers with known HLA typing 
(performed at BWH Tissue Typing laboratory based on a combination of sequence-specific 
SSO and SSP techniques, see above), wherein we observed 100% concordance between the 
two approaches. The LAA phased consensus fastq sequences and HLA typing for each 
sample were derived using a set of publicly available analysis tools (https://github.com/
bnbowman/HlaTools). In total, data was generated from 28 samples corresponding to 18 
different mutations (10 tumor/normal pairs and 8 tumor only cases). The median number of 
subreads generated per sample was 20,120 (range: 7,464 – 40,990). For validation of 
POLYSOLVER-predicted mutations, the subreads from the corresponding samples were 
split into contiguous 76-mers, aligned to alleles comprising the inferred HLA type for the 
individual using Novoalign and visualized using IGV. Only reads that had no more than one 
somatic event of the same type (mismatch, insertion, deletion) as the mutation being 
assessed were retained. After filtering, the median number of 76-mer reads mapping to the 
allele predicted to have the mutation was 1,046 (range: 9 –3,860). Power was calculated 
using the MutationValidator tool as described above, and a threshold of 80% power was 
used in evaluating the mutations.
Identifying changes in gene expression associated with non-silent MHC Class I mutation
Gene expression data were obtained and processed as described32. In short, “Level_3” gene-
level data were obtained from GDAC Firehose (http://gdac.broadinstitute.org). Read counts 
were tallied per gene symbol and divided by the gene symbol’s maximum transcript length 
(as defined by UCSC Genome Browser’s table “knownIsoforms” (hg19 version)). For each 
sample, these values were rescaled to sum to a total of one million, such that expression 
estimates may be interpreted as Transcripts Per Million transcripts (TPM).
For each gene (of ~18,000 quantified pan-cancer), a one-sided Wilcoxon rank-sum test was 
applied to determine whether the mutants (those samples non-silently mutated in any of the 
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six HLA alleles) demonstrated significantly higher expression than the non-mutants. In 
performing this rank-based test, random tie breaks were applied when two samples exhibited 
identical gene expression. Note that in addition to the 18,000 genes tested, “cytolytic 
activity” (defined previously as the geometric mean of GZMA and PRF1 expression32) was 
also included. This process was executed separately per tumor type and excluded tumor 
types for which the count of mutated samples with available expression data was fewer than 
three (which excluded glioblastoma, chronic lymphocytic leukemia, kidney clear cell cancer, 
liver cancer, ovarian cancer, prostate cancer, melanoma, and thyroid cancer). This resulted 
in a matrix of p-values (11 tumor types by 18,000 genes). Fisher’s method was applied to 
each gene to assess its overall significance across the 11 tumor types. Per-cancer and pan-
cancer p-values are presented (Supplementary Table 15). Effect sizes (estimated by taking 
the ratio of median expression in the mutants to median expression in the non-mutants) for 
top genes (defined as those with unadjusted P < 10−10) are depicted in the form of a heatmap 
(Fig. 4d). For this heatmap, row and column orderings reflect hierarchical clustering (on the 
basis of the effect size variable), though dendrograms are not shown.
This entire process was repeated but reversing the directionality of the one-sided Wilcoxon 
rank-sum tests in order to identify genes with lower expression in HLA mutants. Per-cancer 
and pan-cancer p-values for this analysis are presented in Supplementary Table 16, and the 
effect size heatmap appears as Supplementary Figure 5.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Development and validation of POLYSOLVER for inference of MHC class I type
(a) Schematic of the POLYSOLVER algorithm. (b) Comparative performance of 
POLYSOLVER (black bars) and other previously reported algorithms20, 41–44 by library 
size (error bars correspond to s.d.) using the following performance criteria: (i) sensitivity – 
the proportion of all true allele species that are correctly identified by the algorithm; (ii) 
precision – the probability that an inferred allele species is correct; (iii) accuracy – the 
fraction of total number of alleles that are correctly called; and (iv) homozygosity success 
rate – the fraction of all homozygous cases that are correctly inferred.
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Figure 2. POLYSOLVER for the detection of somatic mutations in MHC class I alleles across 
cancers
(a) Schema for detection of somatic changes in HLA genes using POLYSOLVER. Mutation 
detection algorithms Mutect21 and Strelka22 were incorporated for calling point mutations 
and indels respectively, following MHC class I typing of the germline by POLYSOLVER. 
(b) Comparison of somatic HLA mutations identified by TCGA (yellow) across cancers 
using standard approaches to those identified by POLYSOLVER (black) (n=2,545). Green – 
mutations found in common between the two datasets. (c) Number of HLA mutations and 
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the percentage of samples bearing HLA mutations per cancer type identified by standard 
methods (yellow) and POLYSOLVER (black). (d) Validation of mutations using RNA-Seq 
and long read sequencing. RNA-Seq based validation was restricted to 49 samples with 
HLA point mutations (missense, nonsense, non-stop, splice site) identified by exome 
analysis and with available RNA-Seq data. Long read sequencing using Pacific Biosciences’ 
SMRT® technology was performed on HLA alleles from 18 samples with available DNA 
material (Online Methods)27.
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Figure 3. Distribution of HLA mutations across cancers
Distribution of HLA mutations across functional domains and tumor types. Top – 
Distribution of potential loss-of-function events; out of frame (blue) and nonsense mutations 
(red). The histogram summarizes the number of events identified at each position. Central 
panel – Pattern of mutations detected in each tumor type. Bottom – Recurrent events; 
recurrent positions (with disease, allele group) with frequency >= 5 cases/recurrent site are 
shown.
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Figure 4. Distribution of MHC class I mutations and evidence of positive functional selection
(a) Comparison of spectrum of mutations in non-HLA genes and HLA genes. The ratio of 
number of mutations of a particular type to the number of silent mutations is compared 
between the non-HLA and HLA genes for all mutation types (chi-square test, P < 2.2 × 
10−16). (b) Distribution of HLA mutations across exons. (c) Mutations in HLA positions that 
are in actual physical contact with the peptide (contact residues). Left panel – The relative 
orientation of a 9-mer peptide with respect to the HLA and T cell molecules. Positions 2 and 
9 constitute the primary anchors while position 6 forms the secondary anchor with HLA. 
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The remaining position interacts with the T cell molecule. Right panel – The 9 amino acids 
of the peptide and their corresponding HLA contact residues are indicated along the rows 
(orange – HLA interacting anchor positions, blue – T cell interacting positions). The 
histogram depicts the frequency of observed HLA mutations in contact residues 
corresponding to each peptide position29. (d) Killer lymphocyte effector genes are more 
highly expressed in tumors exhibiting MHC Class I mutation. Unbiased statistical analysis 
was employed to find genes more highly expressed in tumors harboring a mutation in an 
MHC class I allele. Heatmap displays color-coded expression ratio of medians (HLA-mutant 
vs. non-mutant samples) for genes (columns) in each cancer type (rows), excluding cancer 
types with fewer than 3 instances of HLA mutation in the cohort. Asterisks (* or **, see 
key) indicate the significance of the association for the given gene in the given cancer type 
according to one-sided Wilcoxon rank-sum test (null hypothesis: expression is not greater in 
the mutants). Cytolytic activity (geometric mean of GZMA and PRF1 expression) is 
included as though a gene. The depicted genes are those for which expression in MHC Class 
I-mutated tumors was most significantly elevated pan-cancer (unadjusted P < 10−10 
combined by Fisher’s method, Supplementary Table 15). Corresponding analysis for genes 
with reduced expression in MHC Class I mutants was also performed (Supplementary Fig. 5 
and Supplementary Table 16).
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